MedTrace Logo

Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures

NCT01147003 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2020-12-17

No results posted yet for this study

Summary

This study will assess the efficacy and safety of BGG492 as adjunctive treatment in patients with partial onset seizures.

Conditions

  • Partial Onset Seizures

Interventions

DRUG

Investigational new drug, company code: BGG492

DRUG

Placebo

DRUG

Investigational new drug, company code: BGG492

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States
  • Bulgaria
  • Germany
  • Hungary
  • Italy
  • Poland
  • Slovakia
  • South Korea
  • Switzerland
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01147003 on ClinicalTrials.gov